ID | 118971 |
Author | |
Keywords | Astaxanthin
Anti-aging medicine
oral hypoglycemic agent
Imeglimin
|
Content Type |
Journal Article
|
Description | Latest Standards of Medical Care in Diabetes-2022 was presented from American Diabetes Association (ADA) on Jan 2022. A topic of Oral Hypoglycemic Agent (OHA) has been imeglimin. It may work through multiple action mechanism such as increasing insulin secretion, decreasing β-cell dysfunction, and preventing death of epithelial cells. Clinically, it decreases HbA1c by 0.5-1.0% for 1000mg twice a day. Diabetes and anti-aging medicine have common background pathophysiologically. Astaxanthin (AX) is the nephroprotective as mitochondrial regulator. AX-functioning mechanism includes to ameliorate insulin resistance and glucose intolerance. Imeglimin normalizes insulin sensitivity and glucose tolerance with maintaining mitochondrial function, suggesting common mechanism.
|
Journal Title |
Edelweiss Journal of Biomedical Research and Review
|
ISSN | 26902613
|
Publisher | Edelweiss Publications
|
Volume | 4
|
Issue | 1
|
Start Page | 1
|
End Page | 2
|
Published Date | 2022-06-23
|
Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
DOI (Published Version) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|